Date: July 1, 2013
Time: 12.00-13.00
Place: Tellus, Karolinska Institutet, Scheeles väg 1, plan 5
“Neuroscience Approaches to Nicotine Addiction Treatment”
Caryn Lerman, PhD
Professor of Psychology in Psychiatry
Department: Psychiatry
Graduate Group Affiliations
Center for Interdisciplinary Research On Nicotine Addiction
Education: B.S. (Psychology), Pennsylvania State University , 1981. M.S. (Psychology) University
of Southern California , 1982. Ph.D. (Clinical Psychology) University of Southern California , 1984.
(Internship in Clinical/Medical Psychology) Boston Veterans Administration Medical Center,
1985.
Caryn Lerman, PhD is Mary W. Calkins Professor in the Department of Psychiatry and Deputy
Director of the Abramson Cancer Center at the University of Pennsylvania. She also directs the
Center for Interdisciplinary Research on Nicotine Addiction. Currently, her research focuses on
understanding the genetic and neural substrates of nicotine addiction and the application of this
knowledge to drug development and delivery. Dr. Lerman is an elected member of the Institute
of Medicine, and a former member of the NCI Board of Scientific Advisors and the National
Human Genome Research Institute Advisory Council. She is currently a member of the National
Advisory Council for the National Institute on Drug Abuse.
Selected Publications
Wang Z, Faith M, Patterson F, Tang K, Kerrin K, Wileyto EP, Detre JA, Lerman C.: Neural
substrates of abstinence-induced cigarette cravings in chronic smokers. Journal of
Neuroscience 27: 14030-14040, 2007.
Loughead J, Wileyto EP, Valdez NJ, Sanborn P, Tang K, Strasser AA, Ruparel K, Ray R,
Gur RC, Lerman C.: Effect of abstinence challenge on brain function and cognition
in smokers differs by COMT genotype. Molecular Psychiatry 14(8): 820-826, 2009.
Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, Gur RC, Lerman C.:
Effects of the alpha4beta2 partial agonist varenicline on brain activity and working
memory in abstinent smokers. Biological Psychiatry 67(8): 715-721, 2010.
Schnoll RA, Patterson F, Wileyto EP, Heitjan D, Shields AE, Asch D, Lerman C. :
Effectiveness of extended duration transdermal nicotine therapy: a randomized
trial. Annals of Internal Medicine 152(3): 144-151, 2010
Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, Benowitz N,
Tyndale RF.: Genetic variation in nicotine metabolism predicts the efficacy of
extended duration transdermal nicotine therapy. Clinical Pharmacology &
Therapeutics 87(5): 553-557, 2010.
Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead J, Divgi C, Blendy JA, Logan J,
Zubieta JK, Lerman C. : Human mu opioid receptor (OPRM1 A118G) polymorphism
is associated with brain mu opiod receptor binding potential in smokers.
Proceedings of the National Academy of Sciences USA 108(22): 9268-9273, 2011.
Mrazek DA, Lerman C. : Pharmacogenomics: facilitating clinical implementation. Journal
of the American Medical Association 306(3): 304-305, 2011.
Perkins KA, Lerman C. : Early human screening of medications to treat drug addiction:
novel paradigms and the relevance of pharmacogenetics. Clinical Pharmacology
and Therapeutics 89(3), 2011
Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C. : Pharmacogenetic
association of the Galanin Receptor (GALR1) SNP rs2717162 with smoking
cessation. Neuropsychopharmacology 37(7): 1683-1688, 2012.
Falcone M, Gold A, Wileyto EP, Ray R, Ruparel K, Newberg A, Dubroff J, Logan J,
Zubieta J-K, Blendy J, Lerman C.: µ-opioid receptor availability in the amygdala is
associated with smoking for negative affect relief. Psychopharmacology 222(4):
701-708, 2012.
Last updated: 08/24/2012
The Trustees of the University of Pennsylvania